A recent systematic review and meta-analysis found that, compared with PDE5 inhibitor monotherapy, combination therapy improves erectile function without increasing treatment-related adverse events. The best outcomes for combination therapy in the study were among the two most difficult-to-treat subgroups: those with prostatectomy-induced ED and those with PDE5 inhibitor monotherapy–resistant ED. The researchers also concluded that postoperative initiation of combination treatment may be associated with improved erectile function among patients undergoing radical prostatectomy.
Learn more about PDE5 inhibitors.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L Windle. Rapid Rx Quiz: Sexual Desire and Performance Medications - Medscape - Apr 11, 2022.
